TREE NEWS update: Hansoh Pharmaceutical’s wholly owned subsidiary and Hansoh Bio, LLC signed a strategic collaboration and license agreement with F. Hoffmann-La Roche Ltd covering a portfolio of antibody-drug conjugate (ADC) projects, including two of Hansoh’s preclinical ADC candidates and multiple ADC programs using Roche-proposed targets developed on Hansoh’s ADC platform. Hansoh will receive a $400 million upfront payment and a $110 million one-year anniversary payment, and is eligible for potential milestone payments exceeding $15 billion tied to development, regulatory and commercialization progress, plus tiered royalties on future product sales.
Hansoh Pharma, Roche Sign ADC Licensing Deal With Over $15B in Milestone Payments
AI take
The size of the headline milestone figure is the story here, but the structure matters more: a modest upfront and anniversary payment against a very large, progress-contingent back end puts most of the value at risk on clinical and regulatory outcomes that are years away. This is a validation of Hansoh's ADC platform as much as of any single candidate, and it signals continued appetite from large pharma for licensing preclinical ADC assets rather than buying them outright. Whether the milestone-heavy template becomes the norm for China-origin ADC deals is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
24m ago
Nearly 75% of Gen Z investors shift portfolios ahead of US midterms
1h ago
CATL Repurchases 186,700 A-Shares for RMB 49.99 Million
1h ago
Dongfeng Group to sell 93.55M Dongfeng shares to Zhongbing Investment for 365M yuan
1h ago
China Approves First Batch of Active Management ETFs, Including Dacheng Dividend ETF
1h ago
Shanghai Stock Exchange’s First Batch of Active ETFs Approved by CSRC
1h ago
Lianxin Micro predicts 2026 nine-month net profit of about 174 million yuan, turning profitable